AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...

ANI Pharmaceuticals is forking over more than half a billion dollars to broaden its rare disease business. | ANI ...

The team at Evercore ISI, for its part, claimed Rasonque’s debut was nothing short of “eye-popping.” The shop is now looking at a potential $500 million in Rasonque sales for the year’s final quarter, ...

VintaBio, which debuted in 2023 as a CDMO focused on cranking out viral vectors for cell and gene therapy production, is having its manufacturing facility and intellectual property ...

Alnylam Pharmaceuticals is seeking a new chief commercial officer as the biopharma announced that its six-year CCO veteran ...

Knudsen’s departure will mark the end of a 27-year run at Novo, with Doustdar telling analysts Wednesday that the outgoing ...

Vanda Pharmaceuticals’ action-packed TV ad for motion-sickness drug Nereus has irked the FDA, which accused (PDF) the company ...

Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...

Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership ...

Would you know the difference between a normal cold and one that has turned into something more serious? | Would you know the ...

Bristol Myers Squibb Canada is partnering with TANK Worldwide and Ogilvy Health on a new “What Summer Leaves Behind” skin ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...